Rubius Therapeutics, Inc
RUBY
RUBY was delisted on the 6th of March, 2023.
76 hedge funds and large institutions have $335M invested in Rubius Therapeutics, Inc in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 22 reducing their positions, and 13 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 22
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
0% more funds holding
Funds holding: 76 → 76 (0)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
57% less capital invested
Capital invested by funds: $771M → $335M (-$436M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$7.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.05M |
| 3 |
JP Morgan Chase
New York
|
+$2.83M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.04M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$1.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$25.4M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
-$13.6M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$13.6M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$7.11M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5M |
RUBY Hedge Fund Activity: Q1 2020 in Review
76 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q1 2020, worth a combined $335M — down 57% from $771M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new RUBY positions and 13 closed out — a net gain of 1 holder — while 24 added to existing stakes and 22 trimmed.
The largest buyer was Artal Group, adding an estimated $7.8M. The largest seller was Capital World Investors, cutting an estimated $25.4M.
- 76 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q1 2020, unchanged from Q4 2019.
- Funds reported $335M of Rubius Therapeutics, Inc stock for Q1 2020, down 57% quarter-over-quarter.
- 14 funds opened new Rubius Therapeutics, Inc positions in Q1 2020 and 13 closed out, a net change of +1 holder.
- The largest Rubius Therapeutics, Inc buyer in Q1 2020 was Artal Group, an estimated $7.8M added.
- The largest Rubius Therapeutics, Inc seller in Q1 2020 was Capital World Investors, an estimated $25.4M sold.
Based on aggregated 13F filings for Q1 2020.